SCAI has elected George D. Dangas, MD, MSCAI, as its new president, succeeding Suni V. Rao, MD, MSCAI. Dr. Dangas will lead the society in advancing interventional cardiology and promoting excellence in patient care.
The Society for Cardiovascular Angiography and Interventions (SCAI) recognized outstanding interventionalists with the Master Interventionalists of SCAI (MSCAI) designation. The recipients demonstrated excellence in invasive/interventional cardiology, innovation, publication, and teaching.
Njambi Mathenge has been selected as the recipient of the SCAI-WIN CHIP Fellowship, offering her additional year of advanced training focusing on complex and high-risk coronary intervention. She will pursue her fellowship at Massachusetts General Hospital and Brigham and Women’s Hospital.
Researchers have developed a pharmacological treatment that improves cardiac function in patients with stiff-heart syndrome, a condition caused by amyloid protein deposition. The new drug reduces amyloid protein deposits and shows promise in reversing established disease symptoms.
The MONITOR-HF trial found that remote pulmonary artery pressure monitoring significantly improved quality of life by 7.1 points at 12 months, with a 44% reduction in heart failure hospitalizations or urgent visits during follow-up. The procedure was safe and reliable, with a high level of adherence to guideline-directed medical therapy.
A new device invented by Emile Daoud and his team at Ohio State University Wexner Medical Center significantly reduces the risk of esophageal injury during heart ablation. The device uses suction force to gently move the esophagus away from the catheter tip, creating a safe pathway for treatment.
The Society for Cardiovascular Angiography and Interventions (SCAI) has created a new recognition program, 30 in Their 30's, to celebrate the contributions of early-career interventional cardiologists. The award highlights leadership and demonstration of SCAI's core values.
Dr. George Dangas has been appointed as the new President of SCAI, a non-profit professional association promoting excellence in interventional cardiovascular medicine. He is an authoritative voice on nonsurgical cardiovascular and valve interventions, and will fulfill various responsibilities including acting as spokesperson for SCAI.
The new guideline provides guidance on the use of cardiac resynchronization therapy and conduction system pacing in patients with indications for pacemakers or heart failure. The authors emphasize the importance of shared decision-making between providers and patients, and highlight areas for future research.